University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > Drug Dosing Toolkit > Juluca

Tivicay + Edurant (Juluca)

Type of Drug: Fixed-Dose Combination
Fixed-dose combinations combine the most commonly prescribed doses of 2 or more medications into a single pill.

Juluca is a combination of Tivicay, an integrase inhibitor, and Edurant, a nonnucleoside reverse transcriptase inhibitor. Integrase inhibitors work by blocking an enzyme (HIV integrase) that the virus needs in order to make more virus. Nonucleoside reverse transcriptase inhibitors prevent HIV from using a differrent enzyme (reverse transcriptase) to make copies of itself.

Approved adult dosing

Tivicay 50 mg + Edurant 25 mg in a single tablet

One Juluca, once daily with a meal

  • Once daily



Notes on taking this medication

  • Take with a meal (do not take without food)
  • Juluca interacts with antacids, laxatives, mineral supplements, and compounds that contain calcium, magnesium, aluminum, or iron, including medicines available over the counter; check with your medical provider before using these.

Possible side effects

  • Juluca has not been studied during pregnancy; tell your medical provider if you become pregnant while taking this drug

See accompanying chart: Tips for Common Side Effects

Same possible side effects as


  • Usually well tolerated; may cause nausea; sleep disturbance; mood changes; headache; muscle aches; rash


  • Usually well tolerated; may cause:
    • Rash (usually is mild to moderate. If severe rash develops, contact your medical provider)
    • Diarrhea
    • Depression, mood changes

See accompanying chart: Tips for Common Side Effects

Scroll over drug name to see other names for the drug.